Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS)
Clinical trial NCT07257380 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07257380
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-30
- Primary completion
- 2029-12-30
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.